Medical weight loss might be on the verge of a further revolution. For starters, people will likely have the option of taking a new class

Employers can anticipate a 6.7% increase in total health benefit costs in 2026 — the steepest in 15 years — according to the 2025 National

Rabat – Smoking kills, so do other diseases, other challenges, and other issues that we either underestimate or are truly unaware of the dangers they

Although scientists are just beginning to study food noise as a concept, individuals who have taken a GLP-1 drug often report that it significantly reduces this distracting, ruminative thinking about food

Hello, everyone, and how are you today? The skies over the Pharmalot campus are soggy this morning, but our spirits are sunny, nonetheless. After all,

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we report on

BellRing Brands, Inc. (NYSE:BRBR) Q4 2025 Earnings Call Transcript November 18, 2025 BellRing Brands, Inc. misses on earnings expectations. Reported EPS is $0.51 EPS, expectations

In a social media post, Republican Sen. Ron Johnson criticized Sen. Bernie Sanders, an independent, for wrongly saying that Affordable Care Act premiums would at

Philadelphia-based Thomas Jefferson University, owner of Jefferson Health, reported an operating loss of $103.8 million (-2.5% operating margin) in the first quarter of fiscal 2026,

Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient education has helped drive early

JCM, Vol. 14, Pages 8209: Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and

Struggling to manage weight can seem like a failure of raw willpower. GLP-1 drugs highlight how misguided that view is – by Matthew C Haug

COVID-19: “As of November 11, 2025, we estimate that COVID-19 infections are growing or likely growing in 20 states, declining or likely declining in 9

For Immediate Release Chicago, IL – November 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks

Within the next two weeks, Novo Nordisk is expected to announce the results of perhaps the most ambitious studies yet of its blockbuster GLP-1 drug

A Yale study suggests GLP-1 drugs like semaglutide slow alcohol breakdown in the liver, raising blood alcohol levels even as they reduce toxic byproducts linked

The results of a patient survey ‘reinforce the importance of dermatology in obesity care,’ according to one of the authors. Medscape Medical News

Research suggests GLP-1 injections like Ozempic and Zepbound may dampen alcohol and drug cravings by lowering dopamine reward responses, but larger human trials are still

Biomolecules, Vol. 15, Pages 1622: Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis

So, my employer used to pay the full premium for a PPO health plan, but as of 2026 that will cost a premium. These are

Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may

Tirzepatide, semaglutide, and liraglutide lead to weight loss in adults with obesity and T1D over 1 year; the greatest weight loss and a modest decrease

As LLY hits ATH today, let’s take a look at LLY’s obesity pipeline after Q3 earnings. 1.) orforglipron: the development story is almost done, and

(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on

On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to

Plus, a profile on the latest startup challenging the dominance of DoorDash and Uber Eats, and a new GLP-1 menu tool

Key Points Weight loss pills could account for 25% of the market share over the long term. The GLP-1 market is expected to grow to

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1

(MedPage Today) — Vanda Pharmaceuticals said its investigational neurokinin-1 receptor antagonist tradipitant reduced nausea and vomiting from semaglutide (Ozempic, Wegovy) in a randomized trial of

Thanks to the GLP-1 revolution, families across the country are negotiating new ways to connect over the holidays.

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the “reward center” of the brain.

The surprising new use for GLP-1s: Alcohol and drug addiction  The Washington Post Taking Ozempic? Yale Researchers Say You’ll Handle Alcohol “Differently” and It Could Be

You might recognize this scene. Lunch was small, you feel full sooner than usual, and by late afternoon you are both a little hungry and

Originally developed for diabetes, GLP-1 drugs like Ozempic are showing remarkable potential in combating addiction. Emerging research suggests these medications can dampen cravings for alcohol

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ahead of the

Healthcare, Vol. 13, Pages 2958: Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence Healthcare doi: 10.3390/healthcare13222958 Authors: Cristina Ștefănescu Elena Alexandra